AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

Despite these challenges, AstraZeneca's diverse portfolio and pipeline provide multiple avenues for growth. The company's focus on high-margin products suggests a strategy aimed at both growth and ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

The combination of a robust pipeline, strategic initiatives in diverse therapeutic areas, and a favorable market valuation underpins Sachin Jain’s Buy recommendation for AstraZeneca’s stock.

For the first half of the fiscal year, analysts anticipate organic sales growth of 0.5%, net sales of $10.7bn and a 2% ...

AstraZeneca PLC on Thursday announced a USD570 million investment in Canada, creating more than 700 jobs, across all areas of the business. The Cambridge-based pharmaceuticals company said the ...

AstraZeneca announced a new investment in Canada to support the company’s move into a larger, more modern facility in Greater ...